학술논문
Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study.
Document Type
Academic Journal
Author
Source
Subject
Language
English
ISSN
0941-4355